MG Med

DXVX, formerly known as MG Med, is a South Korean biotechnology company specializing in molecular diagnostics, genomic analysis, and drug development. Originally founded as a subsidiary of Macrogen, the company has expanded its scope to include digital healthcare and advanced therapeutics, notably mRNA-based vaccines and oncology treatments. DXVX provides a variety of diagnostic services, such as prenatal and postnatal genetic testing, while advancing a clinical-stage pipeline through strategic global partnerships. The company is listed on the KOSDAQ exchange and is currently integrating its diagnostic expertise with new drug discovery platforms. Its strategic direction is heavily influenced by its association with the Hanmi Pharmaceutical leadership through the Coree Group.